Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tenax Therapeutics (NQ: TENX )

4.485 +0.095 (+2.16%)
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tenax Therapeutics

Tenax Therapeutics Inc. (NASDAQ: TENX) Near the Top of Equities by Percentage Gain on 2/6
Via Investor Brand Network
InvestorNewsBreaks – Tenax Therapeutics Inc. (NASDAQ: TENX) Announces $15.6M Public Offering
Via Investor Brand Network
Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions
From Tenax Therapeutics, Inc.
Via Business Wire
NASDAQ:TENX Shareholder Alert: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 02/17/2022 -- Certain directors of Tenax Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties . 
Via SBWire
Investigation for Investors in Tenax Therapeutics, Inc. (NASDAQ:TENX) Shares Announced
San Diego, CA -- (SBWIRE) -- 12/13/2021 -- An investigation was announced for investors of Tenax Therapeutics, Inc. (NASDAQ:TENX) shares over potential securities laws violations by Tenax Therapeutics,... 
Via SBWire
NASDAQ:TENX Investor Notice: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 12/01/2021 -- Certain directors of Tenax Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update
From Tenax Therapeutics, Inc.
Via Business Wire
NASDAQ:TENX Investor Notice: Investigation over Possible Securities Laws Violations by Tenax Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 11/09/2021 -- Tenax Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Set to Join Russell Microcap® Index
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”
From Tenax Therapeutics, Inc.
Via Business Wire
Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders
From Tenax Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.